戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nted by more appropriate terminology, 'renal supportive therapy'.
2 herapy) but not in patients on comprehensive supportive therapy.
3 ne both measured in grams) despite optimized supportive therapy.
4 ly for 24 months while continuing to receive supportive therapy.
5 intensity, and was managed with conventional supportive therapy.
6  improve outcomes of children requiring this supportive therapy.
7 th had specific effects and were superior to supportive therapy.
8  standard cognitive therapy were superior to supportive therapy.
9 l manualized CBT or short-term psychodynamic supportive therapy.
10 2 weeks of either problem-solving therapy or supportive therapy.
11 s of severity of ADHD symptoms compared with supportive therapy.
12 4) compared with those who received enriched supportive therapy.
13  placebo for 7 days, in addition to standard supportive therapy.
14 nary hemorrhage and may be a life-sustaining supportive therapy.
15 are the risks of HSCT with those of lifelong supportive therapy.
16 0 mg/m(2)/d for 10 days is tolerable without supportive therapy.
17  behavioral family therapy, and nondirective supportive therapy.
18 to group hypnotherapy, and 54 to educational supportive therapy.
19 nfants and may be reversible with aggressive supportive therapy.
20  than that of patients receiving personal or supportive therapy.
21  decompensations than did those who received supportive therapy.
22 anxious than patients who received family or supportive therapy.
23 py improves long-term outcomes compared with supportive therapy.
24  standards of care consist of evidence-based supportive therapies.
25  standards of care consist of evidence-based supportive therapies.
26 Mortality-2 (PIM2) mortality risk, and organ supportive therapies.
27 groups stratified by age and number of organ-supportive therapies.
28 y as an adjuvant for other pharmacologic and supportive therapies.
29 nterpersonal psychotherapy, mindfulness, and supportive therapy (-0.82, -1.41 to -0.24).
30 te goal setting to improve rates of DFEs, or supportive therapy, a control condition.
31 FNC (Optiflow, Fisher & Paykel, New Zealand) supportive therapy according to the attending physician'
32 one and chlorambucil, 37 ciclosporin, and 38 supportive therapy alone.
33                                     Enriched supportive therapy also demonstrated statistically signi
34 rrent treatments for COVID-19 are limited to supportive therapies and off-label use of FDA-approved d
35 eekly sessions of problem-solving therapy or supportive therapy and assessed at weeks 3, 6, 9, and 12
36                 The patient was treated with supportive therapy and discontinuation of disease-modify
37 n = 61) or a control treatment consisting of supportive therapy and education (n = 65).
38 nsive behavioral intervention, compared with supportive therapy and education, resulted in greater im
39                         She was treated with supportive therapy and experimental antiviral drug GS-57
40     The TAU consisted of biweekly individual supportive therapy and medication management.
41                                  Advances in supportive therapy and technology have improved the safe
42 measures; no difference was observed between supportive therapy and waiting list on quality of life.
43 y is not a contraindication for any of these supportive therapies, and the criteria for providing the
44 y discontinuing dopamine blockers, providing supportive therapy, and possibly administering medicatio
45 apy would be more effective than educational supportive therapy, and that group hypnotherapy would be
46 iprofloxacin, rifampin, and clindamycin, and supportive therapy appears to have slowed the progressio
47                                 All received supportive therapy appropriate for patients with acute l
48 Individualization of management and adequate supportive therapy are important to obtain the best resp
49           Therapeutic naps, medications, and supportive therapy are recommended for narcolepsy and hy
50 uency of P. gingivalis following initial and supportive therapy compared to conventional treatment.
51 om patient and caregiver) as well as data on supportive therapy, concurrent pharmacotherapy, stimulat
52                                          The supportive therapy condition controlled for nonspecific
53 d MERS-CoV infection is limited to providing supportive therapy consistent with any serious lung dise
54 l or group hypnotherapy or group educational supportive therapy (control group).
55 ontinuing all serotonergic agents, providing supportive therapy, controlling agitation with benzodiaz
56  and pigs, highlighting their potential as a supportive therapy during and after Helicobacter eradica
57 ts are also generally receiving some form of supportive therapy (e.g., fluids, vasopressors, ventilat
58 amidronate and other bisphosponates, used as supportive therapy, effectively reduce the incidence of
59 f CRRT less traumatic, and expand its use as supportive therapy even when complete renal replacement
60 g-term respiratory morbidity, for which only supportive therapies exist.
61 er patients with SIRS respond differently to supportive therapies for shock.
62  placebo and either coping skills therapy or supportive therapy for 12 weeks were assessed at a 6-mon
63                  The role of these agents in supportive therapy for children with cancer is still und
64                                              Supportive therapy for cognitively impaired patients foc
65 ed one additional response or remission over supportive therapy for every 4.4-5.6 patients by the end
66 ronic diseases exercise could be utilized as supportive therapy for IBD patients.
67                                     Enriched supportive therapy fosters illness management through ap
68 smal cold hemoglobinuria requires aggressive supportive therapy, generally supplemented by corticoste
69 %) obtained a DFE compared with those in the supportive therapy group (34.1%) by the 6-month follow-u
70  rate, and a greater remission rate than the supportive therapy group (response rates at week 9: 47.1
71 y to obtain a DFE compared with those in the supportive therapy group (risk ratio = 2.58; 95% CI, 1.9
72 standard cognitive therapy group, 43% of the supportive therapy group, and 7% of the waiting list gro
73 ted improvement compared with members of the supportive therapy group.
74                           Patients receiving supportive therapy had a median survival of 6 weeks.
75 nts together with patient stratification and supportive therapy has resulted in a moderate improvemen
76 ith birth asphyxia, the emphasis has been on supportive therapy; however, there is increasing evidenc
77 l therapy was more effective than family and supportive therapies in preventing psychotic and affecti
78 ns developed management guidelines for other supportive therapies in sepsis that would be of practica
79 ns developed management guidelines for other supportive therapies in sepsis that would be of practica
80 y, personal therapy was more successful than supportive therapy in improving work performance and rel
81 e called into question the safety of ESAs as supportive therapy in patients being treated for oncolog
82                  Current treatment relies on supportive therapies including immunoglobulin replacemen
83              All patients were refractory to supportive therapies, including therapeutic plasma excha
84 ere were also no differences in the need for supportive therapies, including vasopressors, intravenou
85 s indicated in cases refractory to intensive supportive therapy, including low-volume plasma exchange
86                    Concomitant behavioral or supportive therapy increases quit rates and should be en
87 y underscores the necessity of incorporating supportive therapies into preclinical infection models t
88                                              Supportive therapy is a nondirective, psychological trea
89                                     Enriched supportive therapy is an illness management approach tha
90                      Long-term survival with supportive therapy is poor.
91                                              Supportive therapy, mainly bisphosphonates to delay prog
92 ntidotes, addition of PCC or aPCC to maximum supportive therapy may be reasonable for patients with s
93 amage because the former is nonresponsive to supportive therapy, needs long-term anticomplement thera
94 y therapy (SBFT), or individual nondirective supportive therapy (NST).
95 ry disease, (2) problem-solving therapy, (3) supportive therapy, or (4) active comparison conditions
96  therapy, 3 months of weekly emotion-focused supportive therapy, or a 14-week waiting list condition.
97 symptoms were similar to those of family and supportive therapies, particularly in the first 2 years,
98      Finally, recommendations were given for supportive therapy, platelet or red blood cell transfusi
99 ansplant candidates largely according to the supportive therapy prescribed by transplant centers.
100  investigated over the past several decades, supportive therapies remain the mainstay of treatment.
101 lly associated with an E. coli infection and supportive therapy remains the mainstay of treatment.
102           Discontinuation of lipoic acid and supportive therapy resulted in remission.
103                                              Supportive therapy should be applied vigorously to all p
104 onin reuptake inhibitor (SSRI) treatment, or supportive therapy (ST).
105                  These findings suggest that supportive therapies that maintain homeostatic levels of
106               Despite intravenous fluids and supportive therapy the patient's symptoms and condition
107 membrane oxygenation (ECMO) can be used as a supportive therapy to improve outcomes but evidence-base
108                          Despite advances in supportive therapy to prevent complications of sickle ce
109 d a prophylactic therapy, rather than just a supportive therapy, to minimize the progression of lung
110 epression and medical burden) or usual care (supportive therapy, treatment as usual, or case manageme
111 f cognitive-behavioral therapy compared with supportive therapy was conducted in youths with anxiety
112 c behavioral family therapy, or nondirective supportive therapy were evaluated for 2 years after the
113 ho received ciclosporin and one who received supportive therapy) were ineligible, so were not include
114 Shock with ETx or LeTx may require differing supportive therapies, whereas toxin antagonists should l
115               Although infection control and supportive therapies will remain the cornerstone of trea
116                    All participants received supportive therapy with albumin.
117                                      Current supportive therapy with corticosteroids results in a mod
118                                              Supportive therapy, with or without family intervention,

 
Page Top